Primary Ciliary Dyskinesia (PCD)
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Martin PharmaceuticalsNY - New York
1 programInternational Primary Ciliary Dyskinesia (PCD) RegistryN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
ReCode TherapeuticsRCT1100
Martin PharmaceuticalsInternational Primary Ciliary Dyskinesia (PCD) Registry
Clinical Trials (2)
Total enrollment: 2,014 patients across 2 trials
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
Start: Oct 2024Est. completion: Feb 202614 patients
Phase 1Completed
International Primary Ciliary Dyskinesia (PCD) Registry
Start: Jan 2014Est. completion: Dec 20302,000 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,014 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.